INTRODUCTION
The existence of interindividual differences in medication response is well known: variability exists among patients in terms of drug efficacy, dosage requirements, and susceptibility to adverse drug reactions. Pharmacogenetics, the study of how genetic factors influence pharmacokinetics and drug clearance first envisioned by Motulsky 1 in 1957, has a growing role in providing clinically useful prescribing guidance. 2 The US Food and Drug Administration currently lists 139 approved drugs with pharmacogenomic information in their labeling, with categories ranging from information about clinical pharmacology to contraindications, information for patient counseling, and dosing considerations. 3 Boxed warnings, indicating the potential for serious injury or death for individuals with specific genotypes, are in place for select drugs in anesthesiology (codeine), cardiology (clopidogrel), hematology (lenalidomide), infectious disease (abacavir), oncology (arsenic trioxide, everolimus, rasburicase), and neurology (carbamazepine, valproic acid). 3 The hope is that appropriate clinical use of pharmacogenetic testing will contribute to the "triple aim" of improving population health, enhancing patient care, and controlling medical costs. 4 Pharmacogenomics, along with related advances in cancer genomic testing, has received new attention with the launch by President Obama of a new Precision Medicine Initiative. 5 The value of pharmacogenetic testing will depend in part on its acceptability to physicians and patients. The literature contains some data regarding physicians' views of pharmacogenetic testing, [6] [7] [8] [9] [10] and others have explored the views of the general public, 11 but less is known about patients' perceptions. 12 The objective of this study was to explore the views of patients with and without chronic conditions regarding pharmacogenetic testing.
METHODS

Setting and Study Design
This study is part of the Electronic Medical Records and Genomics Network, a consortium funded by the National Human Genome Research Institute to develop approaches to and investigate the utility of the clinical integration of genomic information. 13, 14 Our project is a collaboration between investigators at the Group Health Research Institute and the University of Washington, with study participants at Group Health Cooperative, an integrated health care delivery system that serves more than 600,000 enrollees in Washington and Idaho.
We selected a focus group method because interactive discussions are optimal for exploring questions of acceptability, particularly for topics about which participants may feel underqualified to opine [15] [16] [17] ; participants may feel more comfortable sharing potentially negative views because the group format can provide a feeling of "safety in numbers" for
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Sampling Strategy and Recruitment
Prospective participants were English-speaking adults age 18 years and older identified through Group Health administrative records. To learn about the perspectives of different "types" of patients, we defined 3 patient cohorts ( Table 1 ). As a proxy for patients who were likely to have had personal experiences with trial and error in medication selection, we selected Group Health enrollees who had been (sequentially) prescribed multiple antidepressant medications. 19 To elicit the views of patients for whom pharmacogenetic testing could possibly help to avoid adverse drug events, we identified individuals who had been prescribed carbamazepine. Carbamazepine has been associated with Stevens-Johnson syndrome (toxic epidermal necrolysis) in patients with the HLA-B*1502 allelic variant of the HLA-B gene, which is more common in people of Southeast Asian ancestry 3 ; for this reason, we oversampled for Asian ancestry in this group. For comparison purposes, we identified a third cohort of patients with no particular pharmaceutical concerns or chronic conditions. We mailed 4303 letters to prospective participants describing the study and inviting them to call to enroll; 61 did so, for a total response rate of 1.4%.
Data Collection
In May 2012, we held a pilot session and 2 semistructured focus groups with the antidepressant cohort and 2 focus groups with patients prescribed carbamazepine. In July 2012, we conducted 2 focus groups with patients without chronic illnesses. The investigators used a written discussion guide in all sessions (Table 2) . Each discussion was cofacilitated by 2 members of the study team (SBT and SMF, who introduced themselves as researchers from the University of Washington) and lasted 2 hours. A court transcriptionist attended each session. We provided an informal buffet dinner and paid parking, and each participant was given $50 in cash at the end of each session.
Data Analysis
Our analytic goal was to produce a qualitative description of participants' perceptions of pharmacogenetic testing. 20 We used thematic analysis and a constant comparison approach to coding. 21 Two members of the study team performed several close readings 
RESULTS
Participants were aware of interindividual differences in medication response. Many shared stories about medications that did not work, caused side effects, or were "too strong" or not strong enough. Several related having felt like "guinea pigs" or, in one case, "a test-tube baby" during a process of therapeutic trial and error. A participant in one of the antidepressant groups said, "Sometimes I've been prescribed a medication and then find out it's not maybe doing the job. So we go to the next medication down the list, whereas, for some people, that first one works just fine." The idea that genetics could make a difference in drug response was less familiar, but some participants believed that medication response could be inherited or shared within families.
Participants Believed Pharmacogenetic Testing Could Be Beneficial
Upon introduction to the topic, participants understood the potential of pharmacogenetic testing to optimize prescribing decisions, and they could imagine clear benefits from its use. As one participant put it, "I think it's a great idea. Who wouldn't want more information about the proper medication to take?" Another compared pharmacogenetic testing to riding a bus: "You could jump off anywhere downtown and get to a store, but you want to get off closer to the store you're going to." The value of the test could be even greater in high-stakes situations: a participant who reported that her child is currently awaiting a liver transplant said, "You get the liver, and you're on medication for a long time. If there was a test that would show us which medications are going to work for him, we'd be on that so fast! Because that's a huge life-or-death deal."
Participants in the antidepressant and carbamazepine groups seemed particularly sensitized to the challenges patients can face in finding the right medication and avoiding side effects; many related stories of trial-and-error in the therapeutic odyssey. One person, a participant in one of the depression groups, shared her frustration with prior medication experiences and emphasized the value of identifying the optimal drug more quickly:
Even A par ticipant in one of the carbamazepine discussions said, "The idea that a genetic test-I know there's some controversy there-but that it could help limit, or define, [the best] medication, that's very appealing. I mean, I have had bad years on the wrong thing." Another participant in the same session commented, "If I were taking lithium, or Depakote, or some medicine with a lot of side effects, and this test could say, well, those aren't going to help me, I would want to be taken off of those. So I think there could be a benefit to having a complete workup of the information." Would you be willing to undergo sequencing before being prescribed a specific medication (eg, at your annual physical examination)? What would you want to know about the way(s) in which your additional genetic test information might be stored? Eventually such comprehensive genetic testing might include all genes in the genome, not just those most relevant to drug prescribing. This might mean that other information relevant to your current or future health status would also be generated. What are your impressions about this possibility?
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Potential Negative Effects on Quality of Care and the PhysicianPatient Relationship
The belief that physicians might regard genetic information as more important than other data, possibly to the patient's detriment, was a strong motif. Of greatest concern to participants across all sessions was the possibility that physicians might rely exclusively on pharmacogenetic test results and disregard patients' reports about how a medication is working (or failing to work). A number of patients in the antidepressant and carbamazepine cohorts related incidents in which they felt that their reports of medication problems had not been taken seriously or were actually contradicted. Participants voiced concern about the potential for genetic information to curtail interaction and reduce trust between physicians and patients. In addition to wanting physicians to listen to their concerns and take them into consideration in decision making, participants sought assurance that, in delivering genetic results, the physician would assess the patient's need for support:
Doctors have all this [genetic] information, and you have to look at a person's mental state. Can they handle certain information, or does that send them off to suicide? Or what's it going to do? I was told one time I was getting tested for cancer, and then the doctor walked out of the room. I'm like, "What? What? Who?" I'm sitting there all by myself. "You're testing for cancer?!" So how can you deal with this information? How is that going to be handled?
In contrast, a single participant in the antidepressant group envisioned pharmacogenetic testing as an important step toward what he considered the ideal: "the doctor robot," which would make all clinical decisions on the basis of objective data.
Some participants viewed the use of pharmacogenetic information to deny a particular "good" medication as a form of unfair discrimination, as in this example: "The only thing I don't like about [pharmacogenetic testing is], because of certain percentages, you might not be good on a certain drug, maybe, and they make this whole list of all these good drugs you can't have. So they would refuse certain medicines to you, your whole life." Another participant stated that if there were only one medication available to treat a particular, serious condition, and a pharmacogenetic test indicated that the medication could cause harm, it should be up to the patient-not the physician-to decide whether to take the risk.
Concerns about Access to Genetic Information
Notwithstanding their belief in the value of pharmacogenetic testing, participants identified potential drawbacks to its implementation in the clinic. Concerns about the potential for genetic information to be accessed and (mis)used by unauthorized persons were expressed in all groups. Breach of confidentiality; discrimination in eligibility and coverage for health insurance, long-term care insurance, and disability insurance; employment discrimination; being targeted for pharmaceutical marketing campaigns; and possible misuse by law enforcement agencies were of concern to participants.
Discrimination risks were more readily and more strongly expressed in the antidepressant and carbamazepine groups, together with concerns about social stigma associated with mental health diagnoses, as in this example from the carbamazepine group:
I 
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Participants across all three cohorts also expressed concern about access to pharmacogenetic information within the health care system. Participants suggested that genetic information should be restricted to clinicians with a clear need to know, and that access should be limited to data relevant to a current clinical concern, as in this comment: "If I could have it on a microchip somewhere and say, okay, 'If I'm unconscious, you know, I give medical permission to read this.' Yeah, I probably would go for that. But at the same time, I might say, 'Well, I don't necessarily want it in the chart where the person who's making my appointment can look at it.'" Several other participants suggested that genetic information be given directly to the patient, who would be responsible for determining when it should be shared. One participant commented, "It's us having power over the information. We still want to be a very important part of the equation. And that we get to make some decisions about how it's used."
Patients' Understanding of "Genetic Testing" Is Discordant with Clinicians' Definition
As designed, the focus group guide progressed from discussion of a narrow, single-indication pharmacogenetic test-looking at a small portion of the genome specific to a particular medication-to discussion of wholegenome sequencing, which would include pharmacogenetic results. In each of the sessions, however, we had substantial difficulty focusing participants' conversation on the less comprehensive test scenario. In other words, participants considered "genetic testing" to refer to examination of the entire genome, and most understood the purpose of genetic testing to be predicting one's susceptibility to heritable illness. For example, one participant in the healthy cohort said, "I came in with the idea that this is a testing of your genes, your genetic makeup, to find out if you are more predestined for a certain disease …. Life-threatening things, that's what I thought it was all about." Overall, participants evinced little understanding of the distinction between singlegene tests, panels, and whole-genome sequencing. Participants felt that payers (and to a lesser extent, physicians) would prefer more comprehensive testing approaches for reasons of efficiency and cost-effectiveness.
Whole-Genome Sequencing Was Viewed Differently from Narrower Tests
Once we had explained the differences among single-indication testing, pharmacogenomic panels, and wholegenome sequencing, many participants told us that they regarded whole-genome sequencing as a riskier undertaking than a more narrowly focused test, even if pharmacogenetic information were the primary goal of sequencing. With the generation of additional information, participants believed, the potential for misuse and discrimination would increase as well. Some participants said that comprehensive sequencing would also be more likely to generate information they might not want, particularly for serious health risks they "couldn't do anything about." The potential risks to other family members, given that genetic information about one person says something about their first-degree relatives, were also of concern.
On the other hand, whole-genome sequencing was very attractive to a few participants who reported many seemingly unrelated health problems in themselves and in their families. One such participant said:
For These individuals expressed great interest in comprehensive testing, which they thought could provide a coherent explanation for the multitude of challenges they face.
DISCUSSION
Prior studies on patient views of pharmacogenetic testing have focused on the general public and have generally presented hypothetical scenarios with limited personal relevance to participants. 23, 24 Others have explored the perceptions and values of patients undergoing treatment of life-threatening conditions, who generally express strong support for treatment-focused genetic testing and markedly less concern about the potential risks of discrimination and breach of privacy. [25] [26] [27] This study adds to the perspectives of individuals diagnosed with chronic mental-health conditions. In speaking with participants in the carbamazepine cohort, we learned that many had been prescribed carbamazepine for bipolar disorder rather than seizure disorders (a common indication for this
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"Getting off the Bus Closer to Your Destination": Patients' Views about Pharmacogenetic Testing medication). Our study thus included a majority of individuals with mental health diagnoses. Concerns about privacy, discrimination, and unauthorized access to genetic information are a theme throughout the existing literature. 28, 29 In this study, participants in the antidepressant and carbamazepine groups voiced especially strong concerns about the potential for stigmatization, discrimination, and mistreatment resulting from pharmacogenetic testing and unauthorized access to results. Although these findings may not generalize across entire populations, they highlight an underrepresented perspective that is of particular relevance to ongoing pharmacogenetic research in neuropsychiatry. 2, 30, 31 Our passive recruitment strategy may have generated a greater than usual selection bias.
Pharmacogenetics has often been described as among the most straightforward and near-term applications of genetic information in personalized medicine. 5, [31] [32] [33] [34] An important finding of this study is that some patients who could potentially benefit from pharmacogenetic testing have substantial, deeply held concerns about the tradeoffs involved in allowing genetic information to be generated about them and maintained outside their control. Our participants were not naïve patients; they were very interested in reducing the time to optimal treatment, and many told us they had personally experienced negative effects from current pharmaceutical therapies. Even so, they did not consider pharmacogenetic testing of clear benefit. Our findings are consistent with the results of an Australian study in which chronically ill patients endorsed the potential value of pharmacogenetic testing but emphasized the need for antidiscrimination measures and a holistic approach to diagnosis and prescribing. 35 Avoiding a life-threatening drug reaction is obviously a good thing, but when the benefits are less compelling, patients with chronic illnesses-and perhaps especially those with potentially stigmatizing diagnoses-may decide that the risks of pharmacogenetic testing outweigh the benefits.
We were struck by the strength and prevalence of participants' worries that physicians might overvalue genetic results to the exclusion of patient reports and the detriment of the therapeutic alliance. Although patients understood that such information could be useful in achieving optimal treatment outcomes, they nonetheless expressed misgivings about the possibility that physicians would privilege genetic results over patients' lived experience. This message represents an important counterpoint to the enthusiastic discourse surrounding next-generation sequencing and personalized medicine. If personalized medicine is to be fully embraced by patients, it will be important to ensure that physicians' enactment of "personalization" includes responding to the patient as an individual and not merely a collection of genomic data. 36 Despite the proposed central role of genetics in the coming era of data-driven health care, some patients see pharmacogenetic testing as a potential threat to communication, health care quality, and the physician-patient relationship. Participants in this study wanted pharmacogenetic testing and whole-genome sequencing to complement, not replace, other information about medication response.
CONCLUSIONS
The success of precision medicine, or the provision of "the right drug at the right dose to the right patient," will rely on the broad acceptability of genomic testing by diverse patient cohorts. 5 Our findings suggest that pharmacogenetic solutions designed around the needs and preferences of patients who are basically well may fail to meet the needs of patients with mental health diagnoses or other chronic conditions that may carry social stigma. Health systems and physician practices considering implementation of pharmacogenetic testing must address patient concerns about privacy, discrimination, overreliance on genomic results, and erosion of the physician-patient relationship through public outreach, physician education, and accountable oversight procedures and governance. 
